1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 16
1.2 MARKET ATTRACTIVENESS ANALYSIS 17
2 MARKET INTRODUCTION
2.1 DEFINITION 18
2.2 SCOPE OF THE STUDY 18
2.3 RESEARCH OBJECTIVE 18
2.4 MARKET STRUCTURE 18
2.5 ASSUMPTIONS & LIMITATIONS 19
3 RESEARCH METHODOLOGY
3.1 DATA MINING 20
3.2 SECONDARY RESEARCH 21
3.3 PRIMARY RESEARCH 22
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23
3.5 FORECASTING TECHNIQUES 24
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25
3.6.1 BOTTOM-UP APPROACH 26
3.6.2 TOP-DOWN APPROACH 26
3.7 DATA TRIANGULATION 27
3.8 VALIDATION 27
4 MARKET DYNAMICS
4.1 OVERVIEW 28
4.2 DRIVERS 29
4.2.1 RISING PREFERENCE OF PERSONALIZED MEDICINE 29
4.2.2 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS 29
4.2.3 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT 30
4.2.4 INCREASING GLOBAL INCIDENCE OF CANCER 30
4.3 RESTRAINTS 31
4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS 31
4.4 OPPORTUNITIES 32
4.4.1 ENTRY OF MARKET PLAYERS INTO EMERGING ECONOMIES 32
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 33
5.1.1 THREAT OF NEW ENTRANTS 33
5.1.2 BARGAINING POWER OF SUPPLIERS 34
5.1.3 THREAT OF SUBSTITUTES 34
5.1.4 BARGAINING POWER OF BUYERS 34
5.1.5 INTENSITY OF RIVALRY 34
5.2 SUPPLY CHAIN ANALYSIS 35
5.2.1 R&D AND DESIGNING 36
5.2.2 MANUFACTURING 36
5.2.3 DISTRIBUTION 36
5.2.4 MARKETING & SALES 36
5.2.5 POST-SALES MONITORING 36
5.3 IMPACT OF COVID-19 ON THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 36
5.3.1 OVERVIEW 36
5.3.2 IMPACT ON SUPPLY CHAIN 37
5.3.3 IMPACT ON PRODUCTION 37
5.3.4 IMPACT ON KEY PLAYERS 37
5.3.5 IMPACT ON REGIONS 37
6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES
6.1 OVERVIEW 38
6.2 ASSAYS, KITS & REAGENTS 39
6.3 SOFTWARE & SERVICES 40
7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY
7.1 OVERVIEW 41
7.2 POLYMERASE CHAIN REACTION (PCR) 42
7.3 NEXT-GENERATION SEQUENCING (NGS) 43
8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION
8.1 OVERVIEW 44
8.2 LUNG CANCER 46
8.3 BREAST CANCER 46
8.4 COLORECTAL CANCER 47
8.5 GASTRIC CANCER 47
8.6 MELANOMA 48
9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER
9.1 OVERVIEW 49
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 51
9.3 CONTRACT RESEARCH ORGANIZATIONS 51
9.4 LABORATORIES 52
10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION
10.1 OVERVIEW 53
10.2 AMERICAS 55
10.2.1 NORTH AMERICA 57
10.2.1.1 US 59
10.2.1.2 CANADA 60
10.2.2 LATIN AMERICA 62
10.3 EUROPE 64
10.3.1 WESTERN EUROPE 66
10.3.1.1 GERMANY 68
10.3.1.2 UK 70
10.3.1.3 FRANCE 71
10.3.1.4 ITALY 72
10.3.1.5 SPAIN 74
10.3.1.6 REST OF WESTERN EUROPE 75
10.3.2 EASTERN EUROPE 77
10.4 ASIA-PACIFIC 79
10.4.1 CHINA 81
10.4.2 JAPAN 82
10.4.3 INDIA 84
10.4.4 AUSTRALIA 85
10.4.5 SOUTH KOREA 87
10.4.6 REST OF ASIA-PACIFIC 88
10.5 MIDDLE EAST & AFRICA 90
10.5.1 MIDDLE EAST 92
10.5.2 AFRICA 93
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 95
11.2 COMPETITIVE BENCHMARKING 96
11.3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: COMPANY RANKING 97
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98
11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 98
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 99
11.6.1 PRODUCT APPROVALS AND LAUNCHES 99
11.6.2 JOINT VENTURES 102
11.6.3 EXPANSIONS 105
11.6.4 ACQUISITIONS 105
11.7 FINANCIAL MATRIX 106
12 COMPANY PROFILES
12.1 F. HOFFMANN-LA ROCHE LTD 107
12.1.1 COMPANY OVERVIEW 107
12.1.2 FINANCIAL OVERVIEW 108
12.1.3 PRODUCTS/SERVICES OFFERED 108
12.1.4 KEY DEVELOPMENTS 109
12.1.5 SWOT ANALYSIS 110
12.1.6 KEY STRATEGIES 110
12.2 THERMO FISHER SCIENTIFIC INC. 111
12.2.1 COMPANY OVERVIEW 111
12.2.2 FINANCIAL OVERVIEW 111
12.2.3 PRODUCTS/SERVICES OFFERED 112
12.2.4 KEY DEVELOPMENTS 112
12.2.5 SWOT ANALYSIS 113
12.2.6 KEY STRATEGIES 113
12.3 QIAGEN 114
12.3.1 COMPANY OVERVIEW 114
12.3.2 FINANCIAL OVERVIEW 114
12.3.3 PRODUCTS/SERVICES OFFERED 115
12.3.4 KEY DEVELOPMENTS 115
12.3.5 SWOT ANALYSIS 117
12.3.6 KEY STRATEGIES 117
12.4 BIOMÉRIEUX SA 118
12.4.1 COMPANY OVERVIEW 118
12.4.2 FINANCIAL OVERVIEW 118
12.4.3 PRODUCTS/SERVICES OFFERED 119
12.4.4 KEY DEVELOPMENTS 119
12.4.5 SWOT ANALYSIS 119
12.4.6 KEY STRATEGIES 119
12.5 ILLUMINA, INC. 120
12.5.1 COMPANY OVERVIEW 120
12.5.2 FINANCIAL OVERVIEW 120
12.5.3 PRODUCTS/SERVICES OFFERED 121
12.5.4 KEY DEVELOPMENTS 121
12.5.5 SWOT ANALYSIS 122
12.5.6 KEY STRATEGIES 122
12.6 ARCHERDX, INC. 123
12.6.1 COMPANY OVERVIEW 123
12.6.2 FINANCIAL OVERVIEW 123
12.6.3 PRODUCTS/SERVICES OFFERED 123
12.6.4 KEY DEVELOPMENTS 124
12.6.5 SWOT ANALYSIS 125
12.6.6 KEY STRATEGIES 125
12.7 FOUNDATION MEDICINE, INC. 126
12.7.1 COMPANY OVERVIEW 126
12.7.2 FINANCIAL OVERVIEW 126
12.7.3 PRODUCTS/SERVICES OFFERED 126
12.7.4 KEY DEVELOPMENTS 127
12.7.5 SWOT ANALYSIS 128
12.7.6 KEY STRATEGIES 128
12.8 AMOY DIAGNOSTICS CO. LTD 129
12.8.1 COMPANY OVERVIEW 129
12.8.2 FINANCIAL OVERVIEW 129
12.8.3 PRODUCTS/SERVICES OFFERED 129
12.8.4 KEY DEVELOPMENTS 130
12.8.5 SWOT ANALYSIS 131
12.8.6 KEY STRATEGIES 131
12.9 AGILENT TECHNOLOGIES, INC. 132
12.9.1 COMPANY OVERVIEW 132
12.9.2 FINANCIAL OVERVIEW 132
12.9.3 PRODUCTS/SERVICES OFFERED 133
12.9.4 KEY DEVELOPMENTS 133
12.9.5 SWOT ANALYSIS 134
12.9.6 KEY STRATEGIES 134
12.10 ABBOTT 135
12.10.1 COMPANY OVERVIEW 135
12.10.2 FINANCIAL OVERVIEW 135
12.10.3 PRODUCTS/SERVICES OFFERED 136
12.10.4 KEY DEVELOPMENTS 136
12.10.5 SWOT ANALYSIS 136
12.10.6 KEY STRATEGIES 137
13 APPENDIX
13.1 REFERENCES 138
13.2 RELATED REPORTS 138
14 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 19
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 22
TABLE 3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022-2030 (USD MILLION) 39
TABLE 4 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR ASSAYS, KITS & REAGENTS, BY REGION, 2022-2030 (USD MILLION) 39
TABLE 5 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR SOFTWARE & SERVICES, BY REGION, 2022-2030 (USD MILLION) 40
TABLE 6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 42
TABLE 7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR PCR, BY REGION, 2022-2030 (USD MILLION) 42
TABLE 8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR NGS, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022-2030 (USD MILLION) 45
TABLE 10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR LUNG CANCER, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 11 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR BREAST CANCER, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 12 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR COLORECTAL CANCER, BY REGION, 2022-2030 (USD MILLION) 47
TABLE 13 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR GASTRIC CANCER, BY REGION, 2022-2030 (USD MILLION) 47
TABLE 14 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR MELANOMA, BY REGION, 2022-2030 (USD MILLION) 48
TABLE 15 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION) 50
TABLE 16 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2030 (USD MILLION) 51
TABLE 17 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2030 (USD MILLION) 52
TABLE 18 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR LABORATORIES, BY REGION, 2022-2030 (USD MILLION) 52
TABLE 19 GLOBAL: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION) 54
TABLE 20 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION) 55
TABLE 21 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 56
TABLE 22 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 56
TABLE 23 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 56
TABLE 24 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 57
TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 57
TABLE 26 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 58
TABLE 27 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 58
TABLE 28 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 58
TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 59
TABLE 30 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 59
TABLE 31 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 59
TABLE 32 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 60
TABLE 33 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 60
TABLE 34 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 60
TABLE 35 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 61
TABLE 36 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 61
TABLE 37 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 61
TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 62
TABLE 39 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 62
TABLE 40 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 62
TABLE 41 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 63
TABLE 42 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2022-2030 (USD MILLION) 64
TABLE 43 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 65
TABLE 44 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 65
TABLE 45 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 65
TABLE 46 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 66
TABLE 47 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 67
TABLE 48 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 67
TABLE 49 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 67
TABLE 50 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 68
TABLE 51 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 68
TABLE 52 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 68
TABLE 53 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 69
TABLE 54 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 69
TABLE 55 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 69
TABLE 56 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 70
TABLE 57 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 70
TABLE 58 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 70
TABLE 59 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 71
TABLE 60 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 71
TABLE 61 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 71
TABLE 62 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 72
TABLE 63 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 72
TABLE 64 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 72
TABLE 65 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 73
TABLE 66 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 73
TABLE 67 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 73
TABLE 68 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 74
TABLE 69 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 74
TABLE 70 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 74
TABLE 71 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 75
TABLE 72 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 75
TABLE 73 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 75
TABLE 74 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 76
TABLE 75 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 76
TABLE 76 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 77
TABLE 77 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 77
TABLE 78 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 77
TABLE 79 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 78
TABLE 80 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 79
TABLE 81 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 80
TABLE 82 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 80
TABLE 83 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 80
TABLE 84 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 81
TABLE 85 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 81
TABLE 86 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 81
TABLE 87 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 82
TABLE 88 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 82
TABLE 89 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 82
TABLE 90 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 83
TABLE 91 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 83
TABLE 92 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 83
TABLE 93 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 84
TABLE 94 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 84
TABLE 95 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 84
TABLE 96 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 85
TABLE 97 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 85
TABLE 98 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 85
TABLE 99 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 86
TABLE 100 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 86
TABLE 101 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 87
TABLE 102 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 87
TABLE 103 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 87
TABLE 104 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 88
TABLE 105 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 88
TABLE 106 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 88
TABLE 107 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 89
TABLE 108 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 89
TABLE 109 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION) 90
TABLE 110 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 90
TABLE 111 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 91
TABLE 112 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 91
TABLE 113 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 91
TABLE 114 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 92
TABLE 115 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 92
TABLE 116 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 92
TABLE 117 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 93
TABLE 118 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022–2030 (USD MILLION) 93
TABLE 119 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 93
TABLE 120 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022–2030 (USD MILLION) 94
TABLE 121 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 94
TABLE 122 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98
TABLE 123 PRODUCT APPROVALS AND LAUNCHES 99
TABLE 124 JOINT VENTURES 102
TABLE 125 EXPANSIONS 105
TABLE 126 ACQUISITIONS 105
TABLE 127 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 108
TABLE 128 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 109
TABLE 129 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 112
TABLE 130 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 112
TABLE 131 QIAGEN: PRODUCTS/SERVICES OFFERED 115
TABLE 132 QIAGEN: KEY DEVELOPMENTS 115
TABLE 133 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 119
TABLE 134 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 121
TABLE 135 ILLUMINA, INC.: KEY DEVELOPMENTS 121
TABLE 136 ARCHERDX, INC.: PRODUCTS/SERVICES OFFERED 123
TABLE 137 ARCHERDX, INC.: KEY DEVELOPMENTS 124
TABLE 138 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES OFFERED 126
TABLE 139 FOUNDATION MEDICINE, INC.: KEY DEVELOPMENTS 127
TABLE 140 AMOY DIAGNOSTICS CO LTD.: PRODUCTS/SERVICES OFFERED 129
TABLE 141 AMOY DIAGNOSTICS CO.LTD.: KEY DEVELOPMENTS 130
TABLE 142 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 133
TABLE 143 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS 133
TABLE 144 ABBOTT: PRODUCTS/SERVICES OFFERED 136
TABLE 145 ABBOTT: KEY DEVELOPMENTS 136
15 LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 16
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS, BY REGION, 2022 17
FIGURE 3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: STRUCTURE 18
FIGURE 4 BOTTOM-UP AND TOP-DOWN APPROACHES 25
FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 28
FIGURE 6 DRIVERS: IMPACT ANALYSIS 31
FIGURE 7 RESTRAINTS: IMPACT ANALYSIS 32
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 33
FIGURE 9 SUPPLY CHAIN ANALYSIS: GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 35
FIGURE 10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY PRODUCTS & SERVICES, 2022 (%) 38
FIGURE 11 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2022 & 2030 (USD MILLION) 38
FIGURE 12 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY TECHNOLOGY, 2022 (%) 41
FIGURE 13 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2022 & 2030 (USD MILLION) 41
FIGURE 14 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY INDICATION, 2022 (%) 44
FIGURE 15 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2022 & 2030 (USD MILLION) 45
FIGURE 16 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY END USER, 2022 (%) 49
FIGURE 17 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2022 & 2030 (USD MILLION) 50
FIGURE 18 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY REGION, 2022 (%) 53
FIGURE 19 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2022 & 2030 (USD MILLION) 54
FIGURE 20 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY REGION, 2022 (%) 55
FIGURE 21 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY COUNTRY, 2022 (%) 57
FIGURE 22 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY REGION, 2022 (%) 64
FIGURE 23 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY COUNTRY, 2022 (%) 66
FIGURE 24 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY COUNTRY, 2022 (%) 79
FIGURE 25 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SHARE, BY REGION, 2022 (%) 90
FIGURE 26 BENCHMARKING OF MAJOR COMPETITORS 96
FIGURE 27 MAJOR MANUFACTURERS RANKING, 2022 97
FIGURE 28 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98
FIGURE 29 SALES & OPERATING INCOME MARGIN, 2022 106
FIGURE 30 RESEARCH & DEVELOPMENT EXPENDITURE, 2022 106
FIGURE 31 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 108
FIGURE 32 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 110
FIGURE 33 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 113
FIGURE 35 QIAGEN: FINANCIAL OVERVIEW 114
FIGURE 36 QIAGEN: SWOT ANALYSIS 117
FIGURE 37 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 118
FIGURE 38 BIOMÉRIEUX SA: SWOT ANALYSIS 119
FIGURE 39 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT 120
FIGURE 40 ILLUMINA, INC.: SWOT ANALYSIS 122
FIGURE 41 ARCHERDX, INC.: SWOT ANALYSIS 125
FIGURE 42 FOUNDATION MEDICINE, INC.: SWOT ANALYSIS 128
FIGURE 43 AMOY DIAGNOSTICS CO.LTD.: SWOT ANALYSIS 131
FIGURE 44 AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 132
FIGURE 45 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS 134
FIGURE 46 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 135
FIGURE 47 ABBOTT: SWOT ANALYSIS 136
